The healthcare stock looks ridiculously undervalued.
Pfizer (PFE) stock is in focus NHS England expands Abrysvo RSV vaccine eligibility to 80+ and thsoe in care homes from Apr. 2 ...
A study of nursing home residents demonstrated that vaccination against respiratory syncytial virus reduced their risk for ...
When Lyme disease makes the news, it's typically not for positive reasons — but Pfizer is gearing up to seek regulatory ...
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...
Multiple companies and organizations have announced early results about their COVID-19 vaccines. Here's what we know about ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Gianluca Fioravanti to lead business as it enhances its offer to OEMs Lincotek today announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division a global solutio ...
Pfizer's oncology unit displays mixed Q1 trends as key drugs and biosimilars offset Ibrance declines ahead of earnings on May 5 ...
Pfizer (NYSE:PFE) is accelerating its transformation with acquisitions of Seagen and Metsera to expand in oncology and anti ...
Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S.
The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results